Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignant syndrome

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Neuroleptic Malignant Syndrome (NMS) rarely results from atypical antipsychotic therapy. To date, no information is available on the incidence of NMS with aripiprazole, a newer neuroleptic. Objective: To examine the results of a trial of aripiprazole administered to a 13-year-old Mexican-American girl during the course of NMS. Methods: Vital signs and laboratory values obtained before and during the aripiprazole trial were compared. Results: Aripiprazole administration resulted in a mild increase in tachycardia and brief worsening of serum creatinine kinase level, but did not significantly affect temperature, respiratory rate, or blood pressure. Conclusions: In this adolescent with NMS, aripiprazole treatment was associated with a mild worsening of symptoms.

Original languageEnglish (US)
Pages (from-to)187-188
Number of pages2
JournalInternational Journal of Adolescent Medicine and Health
Issue number2
StatePublished - 2005
Externally publishedYes


  • Aripiprazole
  • Atypical antipsychotics
  • Neuroleptic Malignant Syndrome
  • United States

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignant syndrome'. Together they form a unique fingerprint.

Cite this